本文選題：阿替普酶　切入點：尿激酶　出處：《中西醫(yī)結合心血管病電子雜志》2016年34期 　論文類型：期刊論文

【摘要】：目的觀察阿替普酶與尿激酶分別聯(lián)合依諾肝素鈉對急性ST段抬高型心肌梗死治療的臨床療效。方法我院2016年1月~2016年6月收治的68例急性ST段抬高型心肌梗死患者按照臨床用藥不同將所有患者均分為實驗組與對照組,對照組34例患者給予尿激酶聯(lián)合依諾肝素鈉治療,實驗組34例患者給予阿替普酶聯(lián)合依諾肝素鈉治療,比較兩組患者臨床治療效果。結果實驗組治療無效率為5.9%,對照組治療無效率為20.6%,實驗組患者血管再通率、不良反應發(fā)生率以及死亡率各數(shù)據(jù)明顯優(yōu)于對照組,兩組數(shù)據(jù)均具有統(tǒng)計學意義(P0.05)。結論對于急性ST段抬高型心肌梗死的患者給予阿替普酶聯(lián)合依諾肝素鈉能有效提高患者血管再通率,降低患者不良反應發(fā)生率和臨床死亡率。
[Abstract]:Objective to observe the clinical effect of atropase and urokinase combined with enoxaparin sodium in the treatment of acute ST-segment elevation myocardial infarction. Methods from January 2016 to June 2016, 68 patients with acute ST-segment elevation myocardial infarction were treated in our hospital. All patients were divided into experimental group and control group. 34 patients in the control group were treated with urokinase combined with enoxaparin sodium, and 34 patients in the experimental group were treated with atropase combined with enoxaparin sodium. Results the ineffective rate of treatment was 5.9 in the experimental group and 20.6 in the control group. The data of vascular recanalization rate, adverse reaction rate and mortality rate in the experimental group were significantly better than those in the control group. Conclusion Atiprase combined with enoxaparin sodium in patients with acute ST-segment elevation myocardial infarction can effectively increase the rate of vascular recanalization and reduce the incidence of adverse reactions and clinical mortality in patients with acute ST-segment elevation myocardial infarction.
【作者單位】： 四川省司法警官總醫(yī)院;
【分類號】：R542.22

【相似文獻】

相關期刊論文 前5條

1 張射兵;陸曉和;曲清;段艷冰;;依諾肝素鈉原料藥細菌內毒素檢查方法的研究[J];中國醫(yī)藥導報;2014年12期

2 何奇明;;美國批準依諾肝素鈉針劑用于用于急性STEMI適應癥[J];中國醫(yī)藥導刊;2007年03期

3 彭長生;胡越成;李曦銘;叢洪良;;利伐沙班和依諾肝素鈉在行經皮冠狀動脈介入治療后預防深靜脈血栓形成的效果比較[J];中國臨床研究;2014年01期

4 伯小霞;崔慧斐;;依諾肝素鈉相對分子量的EP與USP分析方法對比研究[J];中國生化藥物雜志;2012年06期

5 ;[J];;年期

，

本文編號：1636564